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Neutrophils play an important role in immunological function. Neutropenic patients are vulnerable to infection, and 
except fever is present, inflammatory reactions are scarce in many cases. Additionally, because infections can worsen 
rapidly, early evaluation and treatments are especially important in febrile neutropenic patients. In cases in which febrile 
neutropenia is anticipated due to anticancer chemotherapy, antibiotic prophylaxis can be used, based on the risk of 
infection. Antifungal prophylaxis may also be considered if long-term neutropenia or mucosal damage is expected. When 
fever is observed in patients suspected to have neutropenia, an adequate physical examination and blood and sputum 
cultures should be performed. Initial antibiotics should be chosen by considering the risk of complications following the 
infection; if the risk is low, oral antibiotics can be used. For initial intravenous antibiotics, monotherapy with a broad-
spectrum antibiotic or combination therapy with two antibiotics is recommended. At 3-5 days after beginning the initial 
antibiotic therapy, the condition of the patient is assessed again to determine whether the fever has subsided or symptoms 
have worsened. If the patient’s condition has improved, intravenous antibiotics can be replaced with oral antibiotics; if the 
condition has deteriorated, a change of antibiotics or addition of antifungal agents should be considered. If the causative 
microorganism is identified, initial antimicrobial or antifungal agents should be changed accordingly. When the cause is not 
detected, the initial agents should continue to be used until the neutrophil count recovers. (Korean J Intern Med 2011;26: 
220-252)
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INTRODUCTION
Background and purpose
The neutrophil is an important component of the 
innate immune system. Neutrophils primarily defend 
the body against microorganisms, and a low number 
of neutrophils indicates that a person is vulnerable to 
infection. Additionally, because neutropenic patients 
lack the leukocytes needed to develop an inflammatory 
response, common inflammatory manifestations that 
are observed in patients within the normal range of 
leukocytes are rarely found. Thus, except in the presence 
of a fever, an accurate diagnosis is difficult and the most 
appropriate time for treatment may be missed. Thus, 
These guidelines will be also published in Infection and Chemotherapy in the Korean language. This secondary publication has been allowed by the 
editors of both journals.
These guidelines were made by the committee “Guidelines for the empirical therapy of neutropenic fever patients based on literature in Korea” under 
the supervision of the National Evidence-based Healthcare Collaborating Agency. These could be different from those of Korean Society of Internal 
Medicine.
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febrile neutropenic patients should be treated differently 
from other febrile non-neutropenic patients [1].
Many countries, including the US and Europe, have 
developed and reported guidelines on approaches to and 
treatments for febrile neutropenic patients. However, the 
pattern of neutropenic fever has changed over the last 20 
years, and the distribution and resistance rate of causative 
microorganisms are known to differ by region, antibiotic 
prophylaxis, and the use of catheters [2]. 
The aim of this study was to investigate the epidemiology 
of infectious diseases and the patterns of resistance and 
antibiotic therapy in febrile neutropenic patients, and 
to develop and suggest empirical treatment guidelines 
for neutropenic fever that fit the circumstances in 
Korea through both a foreign literature review and a 
multidisciplinary study. These guidelines are for adults 
and refer to data published in Korea. These guidelines 
are also applicable to other diseases associated with 
neutropenia, anticancer therapy of malignant tumors, and 
hematopoietic stem cell transplantation (HSCT) recipients.
Organization of a guideline-development commit-
tee
In June 2009, the committee for the development of 
“Guidelines for the Empirical Therapy of Neutropenic 
Fever Patients based on Literature in Korea” was organized 
by receiving recommendations from committee members 
from eight academic societies under the supervision of 
the National Evidence-based Healthcare Collaborating 
Agency (NECA): the Korean Society of Infectious Diseases 
(KSID), the Korean Society for Immunocompromised Host 
Infections (KSIHI), the Korean Cancer Association (KCA), 
the Korean Society of Clinical Microbiology (KSCM), the 
Korean Society of Blood and Marrow Transplantation 
(KSBMT), the Korean Society of Hematology (KSH), the 
Korean Society for Chemotherapy (KSC), and the Korean 
Society of Clinical Oncology (KSCO). The committee 
consists of five infectious diseases physicians, four 
hematology-oncology physicians, one laboratory medicine 
physician, one NECA internist, and one methodologist.
Literature search
For a systematic literature review, the latest guidelines 
of Infectious Diseases Society of America (IDSA) [2], 
National Comprehensive Cancer Network (NCCN) [3], 
the Infectious Diseases Working Party (AGIHO) of the 
German Society of Hematology and Oncology (DGHO) 
[4-13], the First European Conference on Infections in 
Leukaemia (ECIL-1) [14-18], Asia-Pacific [19], and Japan 
[20-27] were collected. To search the literature published 
after the publication of the IDSA guidelines (2002), which 
are relatively widely used, the PubMed (www.pubmed.
gov) search engine was used. The search period was 
from January 2002 to October 2009. Search entries for 
neutropenia were “neutrop*nia,” “granulocytop*nia,” and 
“leu?op*nia.” The search entries for tumor were “cancer,” 
“malignancy,” “neoplasm,” “leukemia,” “lymphoma,” 
“hematolog*” and the combination of “(stem or marrow) 
AND transplantation.” Literature regarding fever and 
antibiotic therapy were searched by combining “fever 
or febrile,” “anti-infect*,” “anti-bacteri*,” “anti-microb*,” 
“anti-bio*,” “anti-fung*,” and “anti-vir*.” To find Korean 
studies published in foreign journals, the Korean literature 
was also searched through the PubMed engine.
Major reports published in Korea over the last 10 years 
were searched through the database of Korean Studies 
Information (http://kiss.kstudy.com) and KoreaMed 
(http://www.koreamed.org). Search entries were 
combination of “neutrophil”  or “granulocyte,” “fever” 
and “infection” by Korean letters. Reports before 2000 
were collected if they were considered to be related to the 
development of this treatment guideline. Related literature 
was added by searching references of the collected 
literature, manually if necessary. The searched Korean 
literature totaled 39 reports (4 review articles and 35 
original articles). In total, 218 references are cited; 27 were 
from the Korean literature.
Formulation of key questions
To create empirical treatment guidelines for febrile 
neutropenic patients, the following major categories 
were selected: definition of neutropenia and fever, initial 
evaluation and risk of infection, antibiotic prophylaxis, 
initial antibiotic therapy for febrile neutropenic patients, 
re-evaluation after 3-5 days and change of antibiotics, 
use of glycopeptides, catheter-related infections, and 
antifungal therapy.
The subcommittee of infectious diseases specialists 
formulated key questions in each area. Key questions were 
determined by reviewing foreign treatment guidelines and 
recommendations that could cause problems in Korean 
circumstances. 
Consensus
Recommended answers to the key questions were based 
on major guidelines and literature, and the final version of 
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these recommendations was made by a consensus of the 
guideline development committee.
Strength of recommendations and quality of evi-
dence
For strength of recommendations and quality of 
evidence, the methods used in the latest guidelines of 
IDSA were accepted (Table 1) [28].
Evaluation by external specialists
Questionnaire survey
To evaluate the key questions and recommended 
answers given by a consensus of the committee for the 
development of these guidelines, a questionnaire survey 
on the guidelines was performed. The questionnaire asked 
whether each recommendation could be accepted in Korea 
and whether the strength of each recommendation was 
graded appropriately.
The subjects of the questionnaire survey were infectious 
diseases physicians and hematology-oncology physicians 
to enhance its specialty, and physicians in general 
hospitals operating HSCT centers around the nation to 
ensure representativeness. 
Symposia of related academic societies
The final treatment guidelines, which reflected opinions 
from the internal review and the questionnaire survey, 
were presented in symposia of major related societies 
through 2010. Additionally, its revision and spread are 
planned after acceptance of opinions of and evaluations by 
various specialist groups.
DEFINITION OF NEUTROPENIA AND FEVER
Fever is defined as an increase in body temperature 
to over 38.0°C, using a tympanic thermometer, or 
to over 37.5°C, using an axillary thermometer. If the 
tympanic or axillary temperature is thought to be in-
accurate or the oral temperature is mainly measured, 
fever is defined as an increase in a single oral tem-
perature to over 38.3°C or to over 38.0°C for more 
than 1 hour.
Neutropenia is defined as an absolute neutrophil 
count less than 500/mm3 or expected to be less than 
500/mm3 within 2-3 days.
Major foreign guidelines, including those of IDSA and 
NCCN, define fever as an increase in oral temperature 
to over 38.3°C once or to 38.0°C for more than 1 hour 
[2,3,11,19,22]. In the questionnaire survey conducted with 
33 medical staff members in 28 hospitals in Korea, 79% 
of the respondents answered that fever was defined as 
an increase in body temperature in two locations to over 
38.0°C or an increase in body temperature to over 38.0°C 
for 1-2 hours [29]. Only two respondents (6%) measured 
oral temperature, and 31 (94%) said that they measured 
axillary or tympanic temperature [29]. Thus, the definition 
of fever using tympanic or axillary temperature, as stated 
in the guidelines developed by a consensus of specialists 
in Asia-Pacific countries, is more pragmatic in Korea [19]. 
Table 1. Definition of strength of recommendation and quality of evidence
Category, grade    definition
Strength of recommendation
A Good evidence to support a recommendation for or against use.
B Moderate evidence to support a recommendation for or against use.
C Poor evidence to support a recommendation.
Quality of evidence
I Evidence from ≥ 1 properly randomized, controlled trial.
II Evidence from ≥ 1 well-designed clinical trial, without randomization, from cohort or case-controlled 
  analytic studies (preferably from > 1 center), from multiple time-series, or from dramatic results from 
  uncontrolled  experiments.
III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or
  reports of expert committees.
Adapted from the Canadian Task Force on the Periodic Health Examination [28].
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The correlation between tympanic and core temperatures 
has been well studied [30,31], and a correlation in febrile 
neutropenic patients has also been reported [32]. Notably, 
even in patients with no or only mild fever, the oral 
temperature may read higher than the actual temperature 
in the presence of oral mucositis [33].
When the neutrophil count is reduced to less than 500/
mm3, the risk of infection is increased [34]. In a study on 
the neutrophil count, measured at the time of fever, and 
the frequency of infection in leukemia patients undergoing 
chemotherapy, over 70% of febrile patients showed a 
neutrophil count of less than 500/mm3; furthermore, fever 
with a lower neutrophil count was caused by infection in 
more cases [35]. A questionnaire survey involving Korean 
medical institutions also revealed that 31 (94%) of the 
respondents used the same aforementioned definition 
[29].
INITIAL EVALUATION
Fever in neutropenic patients can be caused not only by 
bacterial or fungal infection, but also by non-infectious 
causes, such as drugs, blood transfusions, and the use of 
granulocyte colony stimulating factor. Because infection 
in neutropenic patients proceeds rapidly and symptoms 
or signs of an inflammatory response are rarely observed 
even in cases of infection, a close initial evaluation is 
necessary [36].
The initial evaluation of suspected febrile neutropenic 
patients should focus on determining possible causative 
sites or microorganisms. As soon as a patient is admitted 
to a hospital, a history should be taken, a physical 
examination should be conducted, and blood and other 
specimens should be collected for bacterial and fungal 
cultures.
A thorough history should include information on 
associated disease (s), currently used drug (s), the latest 
anticancer therapy, and whether a family member 
currently has an infectious disease. Decisions should be 
made regarding whether to hospitalize the patient and/or 
to use prophylactic antibiotics.
The physical examination should evaluate common 
sites of infection, such as the oral mucosa, paranasal 
sinuses, ear, chest, abdomen, skin, nails, groin, anal and 
vaginal areas, vascular catheter insertion sites, and bone 
marrow biopsy sites [2,3]. It is important to pay attention 
to even small symptoms and signs, including mild pain 
or tenderness at these sites [2]. Initial blood tests should 
include a complete blood cell count, differential blood 
count, blood urea nitrogen, creatinine, electrolytes, total 
bilirubin, and a liver function test. If necessary, based on 
symptoms, an arterial blood gas analysis or urinalysis 
should also be conducted.
Microbiological cultures should be performed before the 
administration of antibiotics. At least two pairs of blood 
cultures should be conducted. When a central venous 
catheter is present, culture of blood collected through the 
catheter is recommended. Some specialists insist that 
unless the differential time to positivity is calculated, 
specimens from a central venous catheter alone can be 
cultured without peripheral venous samples because 
catheter-related infection may occur [3].
In cases with no sign or symptom of infection, specimens 
from the nasal cavity, oropharynx, urine, stool, and 
rectum do not need to be cultured, except for the purpose 
of hospital-related infection control [2,3]. However, stool 
cultures and Clostridium difficile toxin assays can be 
conducted for patients with diarrhea, and rotavirus or 
norovirus infections can be checked in the winter and 
during epidemic periods. Urine culture is recommended 
when there are symptoms of urinary tract infection, 
when a urethral catheter has been inserted, or when a 
urinalysis reveals abnormal findings. Although a colony-
stimulating factor (CSF) examination is not absolutely 
necessary, it should be conducted in cases with symptoms 
of central nervous system infection. The presence of 
hemorrhagic tendencies and thrombocytopenia should 
be evaluated and, if necessary, appropriate interventions, 
such as transfusions, should be performed before the 
examination. For newly observed skin lesions or those of 
unknown causes, biopsies should be conducted and the 
results of microbiological cultures and histopathological 
findings should be evaluated. In cases with bullous lesions 
on the mucous membranes or skin, the presence of herpes 
simplex virus (HSV) infection should be determined. If a 
respiratory manifestation is present, a chest X-ray should 
be taken. Additionally, even with no symptoms, basal 
chest X-rays are recommended for comparison with future 
images when respiratory symptoms are present. Although 
there may be no abnormality on chest X-rays because 
there is no inflammatory response in neutropenic patients, 
approximately half of these patients can show evidence 
of pulmonary infiltration on chest computed tomography 
(CT) images [2,37].
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RISK OF INFECTION
To determine the risk of serious infectious diseases 
in febrile neutropenic patients, the risk index of the 
Multinational Association for Supportive Care in Cancer 
(MASCC) can be used. A patient with a total score of 21 
points or above is classified as low-risk [38]. Since the 
1980s, many studies identifying patients who can be 
treated with oral antibiotics or as outpatients have been 
conducted by classifying their risk [38-41]. The MASCC 
risk index was developed through a prospective study by 
scoring weights based on factors influencing the prognosis 
of neutropenic fever using various factors, such as age, 
gender, underlying disease (s), the therapeutic condition 
of a cancer, associated disease (s), history of treatments 
for previous infectious diseases, and blood test results, in 
1,139 subjects from 15 countries [38]. When the MASCC 
risk index score of 21 points or above was classified as the 
low-risk group, the positive and negative predictive values 
of no serious complications of neutropenic fever were 
94% and 39%, respectively. NCCN differentiates between 
low- and high-risk groups by adding clinically important 
factors not included in the MASCC risk index [3]. A study 
analyzing the risk of severe complications or death caused 
by infection in Koreans has also been reported. Among 
the factors that could be initially assessed in febrile 
neutropenic patients visiting the emergency department, 
the risk factors of a continuous fever lasting 3 or more 
days were a visit within 10 days after the last anticancer 
therapy and newly observed pulmonary infiltration. Risk 
factors of septic shock were a change in consciousness and 
a creatinine clearance of less than 75 mL/min, and those 
of death were tachycardia, reduced creatinine clearance, 
a change in consciousness, and an associated pathogenic 
condition. Additionally, duration of neutropenia was 
significantly related with the mortality rate and incidence 
rate of septic shock [42]. The risk factor of death due 
to acute leukemia during a hospital stay in patients 
undergoing anticancer therapy was a previous or current 
fungal infection [43].
ANTIBIOTIC PROPHYLAXIS
Is antibiotic prophylaxis necessary for expected 
febrile neutropenic patients?
1.   Antibiotic prophylaxis is recommended for patients at 
intermediate-to-high risk of infection (A-I).
2.  Fluoroquinolones are recommended as prophylactic 
antibacterial agents (A-I).
Because neutropenic patients have a high risk of infec-
tion, antibiotic prophylaxis can be helpful. However, if an-
tibiotic prophylaxis is applied to all neutropenic patients, 
including those at a relatively low risk of infection who do 
not need it, antibiotic-resistant bacteria may emerge and 
excessive medical costs may be incurred. Thus, it is im-
portant to determine which patients will be most helped 
by antibiotic prophylaxis and the appropriate period for 
Table 2. Overall infection risk in cancer patients by type of disease or therapy
Overall infection risk Disease or therapy examples Antimicrobial prophylaxis
Low risk of infection Anticipated neutropenia < 7 days
Standard chemotherapy regimens for most solid
  tumors
Bacterial: none
Fungal: none
Viral: none, unless prior HSV episode
Intermediate risk of infection Anticipated neutropenia 7-10 days
Autologous HSCT
lymphoma
Multiple myeloma
Chronic lymphocytic leukemia
Purine analog therapy: fludarabine, clofarabine,  
  nelarabine, 2-CdA
Bacterial: consider fluoroquinolone prophylaxis
Fungal: consider prophylaxis
Viral: during neutropenia, at least 30 days after HSCT
High risk of infection Anticipated neutropenia greater than 10 days
Allogeneic HSCT
Acute leukemia: induction, consolidation
Alemtuzumab therapy
Bacterial: consider fluoroquinolone prophylaxis
Fungal: consider prophylaxis
Viral: during neutropenia, at least 30 days after HSCT
HSV, herpes simplex virus; HSCT, hematopoietic stem cell transplantation; 2-CdA, 2-chlordexoyadenosine (also known as cladribine).
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prophylaxis. Patients for whom prophylactic antibacterial, 
antifungal, or antiviral treatment is recommended are 
shown in Table 2 [3].
While past studies on antibiotic prophylaxis mainly used 
sulfamethoxazole/trimethoprim, many studies conducted 
since the late 1990s have used fluoroquinolones. According 
to a meta-analysis on the use of prophylactic antibacterial 
agents [44], the group using prophylactic antibacterial 
agents showed a lower mortality rate following infection 
and a lower total mortality rate compared with those not 
using prophylactic antibiotics or using placebo; the effects 
in the fluoroquinolones group were particularly evident. 
Another meta-analysis reported that fever, infection 
caused by Gram-negative bacteria, microbiologically 
documented infection, and total infection occurred less 
in patients using prophylactic fluoroquinolones than in 
those using sulfamethoxazole/trimethoprim or placebo. 
However, even prophylaxis using fluoroquinolones did 
not reduce Gram-positive bacterial infection, fungal 
infection, or the mortality rate [45]. Additionally, although 
there was concern about the emergence of antibiotic-
resistant bacteria in the group using prophylactic 
antibacterial agents, resistance was not increased in the 
fluoroquinolone group. However, some reports have stated 
that resistant Gram-negative bacteria increased during 
fluoroquinolone prophylaxis, and this tendency improved 
after discontinuation of the prophylaxis; close attention 
to this is necessary [46]. That is, evidence for the use of 
prophylactic antibacterial agents such as fluoroquinolones 
exist in intermediate-to-high risk groups, but the long-
term effects of antibiotic prophylaxis have not yet been fully 
determined; the emergence of resistant bacteria should be 
continuously monitored and antibiotic prophylaxis should 
be optimized in each hospital.
Ciprofloxacin or ofloxacin, which were widely used 
for prophylaxis in the past, had good antimicrobial 
activities against Gram-negative bacteria but relatively 
poor activities against Gram-positive bacteria. Studies 
using levofloxacin showed outstanding antimicrobial 
activity against Gram-positive bacteria as a prophylactic 
antibacterial agent for solid tumor and lymphoma 
patients [47] and solid tumor, lymphoma, and acute 
leukemia patients [48]. Both were large-scale studies 
that included over 300 subjects in each group. Infection 
caused by Gram-positive bacteria or bacteremia that 
was not prevented by fluoroquinolones decreased in the 
levofloxacin group. Although infection caused by Gram-
negative bacteria was also significantly decreased, the 
total mortality rate and the mortality rate due to infection 
were not significantly different between the two groups.
In Korea, a study was performed on the effects of 
prophylactic antibacterial agents in acute leukemia 
patients undergoing anticancer therapy [49]. The study 
used ciprofloxacin and roxithromycin for prophylaxis, and 
the patients using these prophylactic antibacterial agents 
showed fewer Gram-negative bacterial infections, but more 
Gram-positive bacterial infections. Additionally, the total 
infection rate and the mortality rate following infection 
did not differ between the two groups. As of 2010, the 
hospital does not use prophylactic roxithromycin.
Until when should antibiotic prophylaxis be used?
3.   Antibacterial prophylaxis is administered until 
neutrophil recovery (absolute neutrophil count 500-
1,000/mm
3
) (B-III).
Because there has been no prospective clinical study 
comparing the effect of the same drug for different 
periods to determine the proper administration period 
of prophylactic antibacterial agents, it is difficult to 
determine the appropriate end point of antibacterial 
prophylaxis. Most previous studies that showed effective 
outcomes of antibacterial prophylaxis used antibacterial 
agents from the beginning of anticancer therapy or within 
48-72 hours after anticancer therapy until recovery of the 
absolute neutrophil count, and there was no difference in 
the preventive effects based on the administration period 
[48,50-53].
Is antifungal prophylaxis necessary?
4.  Antifungal prophylaxis is recommended to prevent 
fungal infections in patients whose neutropenia is 
expected to last for more than 7 days. Appropriate 
antifungals for this purpose include posaconazole (A-
I), fluconazole (B-I), itraconazole oral solution (B-I), low-
dose amphotericin B deoxycholate (B-I), and low-dose 
liposomal amphotericin B (C-II).
5.  Antifungal prophylaxis is recommended to prevent 
fungal infections in allogeneic HSCT recipients. 
Appropriate antifungals for this purpose include 
posaconazole (A-I), fluconazole (A-I), micafungin (B-
I), and itraconazole intravenous injection followed by 
itraconazole oral solution (B-I).
When prolonged neutropenia is expected, such as 
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in patients undergoing remission induction therapy or 
maintenance/consolidation therapy due to a hematologic 
malignancy or those receiving allogeneic HSCT, antifungal 
prophylaxis is recommended [2,3]. Azoles have been 
widely used as prophylactic antifungal agents because of 
their favorable costs, adverse reaction profiles, and they 
allow the selection of other therapeutic antifungal agents 
for breakthrough fungal infections during antifungal 
prophylaxis.
A meta-analysis on antifungal prophylaxis revealed 
that the total mortality rate (relative risk [RR], 0.84; 95% 
confidence interval [CI], 0.74 to 0.95), fungus-related 
mortality rate (RR, 0.55; 95% CI, 0.41 to 0.74), invasive 
fungal infection, definite invasive fungal infection, definite 
invasive Candida infection, and the use of empirical 
antifungals decreased in the group using prophylactic 
antifungal agents compared with the groups not using 
prophylaxis or using a placebo [54]. Although fluconazole 
as a prophylactic antifungal agent tended to increase 
invasive aspergillosis, antifungal agents with specificity 
for filamentous fungi, such as itraconazole, resulted in less 
invasive aspergillosis infections [54]. 
Many studies have been performed on fluconazole, 
which has been shown to be very effective. Prophylaxis 
using 400 mg fluconazole per day reduced invasive fungal 
infections and the infection-related mortality rate in 
allogeneic HSCT recipients [55,56]. However, some reports 
stated that f luconazole did not significantly prevent 
invasive fungal infection in acute leukemia or autologous 
HSCT patients [57-59]. Additionally, studies using less 
than 400 mg prophylactic fluconazole per day did not find 
any significant difference in invasive fungal infections or 
mortality rates [60-62].
Itraconazole has antimicrobial activity against 
Aspergillus species and its preventive effect is thought to 
be superior to that of fluconazole; however, a study that 
directly compared fluconazole and itraconazole showed 
no significant differences in the all-cause mortality rate, 
fungus-related mortality rate, definite invasive fungal 
infection, invasive Candida infection, or superficial fungal 
infection [63-69]. When the efficacy of itraconazole was 
compared with that of fluconazole, limiting the studies 
to those using itraconazole oral solution, not the capsule, 
invasive fungal and Candida infections were decreased 
significantly [65-69]. The combination of itraconazole 
with vincristine or cyclophosphamide should be avoided 
because of the potential for drug interactions, and the 
administration of itraconazole should be performed 
cautiously in patients with a history of heart failure 
or lower cardiac output because of its cardiotoxicity 
[70] (intravenous itraconazole is not approved as a 
prophylactic antifungal agent by the Korea Food and Drug 
Administration [KFDA] as of 2009).
Posaconazole oral solution has a wide range of 
antifungal activity against Candida and filamentous fungi 
[71,72]. An assessment of the effect of prophylactically 
administered posaconazole in acute myelogenous 
leukemia and myelodysplastic syndrome patients found 
that proven or probable invasive fungal infection and 
invasive aspergillosis were observed less and the survival 
rate was significantly higher in the posaconazole group 
than in the fluconazole or itraconazole groups. However, a 
higher frequency of adverse reactions was found, including 
increases in bilirubin and liver enzyme levels [73] 
(posaconazole is approved as a prophylactic antifungal 
agent for neutropenic fever by the KFDA, but is not on the 
market and is purchased through the Korea Orphan Drug 
Center as of 2009).
A study that compared micafungin and fluconazole as 
prophylactic agents in 882 allogeneic or autologous HSCT 
recipients reported that the success rate of prophylaxis 
(80.0% vs. 73.5%; 95% CI, 0.9 to 12) was higher and 
the frequency of invasive aspergillosis was lower in the 
micafungin group; however, the mortality rate was not 
significantly different between the two groups [74]. 
Moreover, no significant difference was found in the 
frequency of adverse reactions or the discontinuation rate 
between the two groups. However, a limitation of this 
study was that over 70% of the subjects were autologous 
HSCT or low-risk allogeneic HSCT recipients. A recent 
study insisted that the incidence of fungal infection 
was not significantly different between micafungin and 
fluconazole groups [75].
Although low-dose amphotericin B deoxycholate (0.2 
mg/kg/day or 0.5 mg/kg 3 times per week) showed much 
better preventive effects than fluconazole, it is difficult to 
use in many cases because of its toxicity [76,77]. Because 
the amphotericin B lipid formulation has less toxicity 
than amphotericin B deoxycholate, studies on its use to 
prevent neutropenic fever have been conducted. Although 
a preventative effect of 50 mg (low-dose) liposomal 
amphotericin B was not observed in previous small-
scale studies [78-80], recent large-scale studies found 
that it decreased invasive fungal infection and infection-
related mortality rates [81]. Inhalation of amphotericin 
B deoxycholate has also been attempted to prevent 
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pulmonary fungal infection [82-84].
In Korea, a study investigated the effects of itraconazole 
oral solution and fluconazole as prophylactic agents and 
showed that the preventative effects of the two drugs were 
not significantly different [85]. However, administration 
compliance was lower due to gastrointestinal adverse 
reactions in the itraconazole group.
Until when should antifungal prophylaxis be used?
6.  Use of prophylactic antifungal agents should be 
considered at least until neutrophil recovery (absolute 
neutrophil count 500-1,000/mm
3
) (B-III).
7.   Use of prophylactic antifungal agents should 
be considered until the discontinuation of 
immunosuppressants if immunosuppressants are used 
after allogeneic HSCT (B-III).
Although it is difficult to find studie s with reliable 
evidence for the determination of the end point of 
antifungal prophylaxis, they are generally administered 
until recovery of absolute neutrophil counts occurs 
[55,57,59,62,79,81,86-93]. However, allogeneic HSCT 
recipients may require antifungal prophylaxis even after 
neutrophil recovery, and NCCN recommends continuing 
prophylaxis until 75 days after HSCT [3]. Additionally, 
when graft versus host disease (GVHD) is observed, the 
period of antifungal prophylaxis can be extended. A recent 
large-scale study reported that an average of 112-day 
prophylactic posaconazole therapy effectively prevented 
invasive fungal infection in patients with GVHD [94].
Does Pneumocystis jirovecii need to be prevented?
 8.  Prophylaxis against P. jirovecii is recommended in 
allogeneic HSCT recipients (A-I).
 9.  Use of prophylaxis against P. jirovecii should be 
considered in cases of autologous HSCT, high-dose 
corticosteroid therapy (e.g., the equivalent of 20 mg/
day or more of prednisone for 4 weeks or more), 
administration of T-cell-depleting agents, such as 
fludarabine (B-II) or anticancer therapy due to acute 
leukemia (e.g., acute lymphocytic leukemia) (B-III).
10.  Use of sulfamethoxazole/trimethoprim (A-I) is 
recommended for prevention of P. jirovecii. If the 
patient is intolerant to the drug, consider using 
dapsone or aerosolized pentamidine (B-II).
Sulfamethoxazole/trimethoprim can be used to 
prevent P. jirovecii in acute leukemia patients and HSCT 
recipients, and its preventive effect is excellent [95-
97]. A meta-analysis on the prevention of P. jirovecii in 
immunocompromised patients (with the exception of 
human immunodeficiency virus [HIV] patients) showed 
that the P. jirovecii-related mortality rate was significantly 
reduced in the sulfamethoxazole/trimethoprim group 
(RR, 0.17; 95% CI, 0.03 to 0.94) [96,97]. Because P. 
jirovecii infection is known to increase in patients 
using alemtuzumab or fludarabine because of chronic 
lymphocytic leukemia or lymphoproliferative disorders 
[98-100], prevention of P. jirovecii can be considered. 
For this, 160/800 mg or 80/400 mg sulfamethoxazole/
trimethoprim is administered, and if there is a concern 
about adverse events, such as bone marrow suppression, 
160/800 mg is administered every other day. When the 
drug was used every other day, its preventive effect did not 
differ from that of daily administration (RR of pneumonia, 
0.82; 95% CI, 0.61 to 1.09). Significantly more patients 
who took the drug daily discontinued it due to adverse 
reactions (RR, 2.14; 95% CI, 1.73 to 2.66) [101]. However, 
these results should be interpreted carefully because 
the study was performed not with neutropenic patients, 
but with HIV infection patients. If sulfamethoxazole/
trimethoprim is difficult to administer because of 
leukopenia, dapsone or aerosolized pentamidine can 
be used [102]. However, dapsone and aerosolized 
pentamidine produce a weaker preventive effect against 
P. jirovecii than sulfamethoxazole/trimethoprim and can 
lead to additional infections and a higher mortality rate 
following infection [103].
Is antiviral prophylaxis necessary?
11.  Antiviral prophylaxis against HSV is advised in 
HSV-seropositive patients in the case of allogeneic 
HSCT (A-I), autologous HSCT at high risk for 
mucositis (A-II), induction or re-induction therapy for 
acute leukemia (B-I), or the use of T-cell-depleting 
monoclonal antibodies (e.g., alemtuzumab) (B-II).
12.  Consider using prophylactic antiviral agents in 
consecutive chemotherapy if HSV was reactivated in 
the previous chemotherapy (B-III).
13.  Acyclovir or valacyclovir is recommended for the 
prevention of HSV (A-I).
If antiviral prophylaxis against HSV is not conducted 
for allogeneic HSCT recipients, approximately 62-80% of 
HSV IgG-seropositive patients show reactivation of the 
virus, while only 1-1.5% of HSV IgG-seronegative patients 
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experience viral reactivation [104,105]. For autologous 
HSCT, a lack of antiviral prophylaxis leads to lesions 
caused by HSV in approximately 2-6% of cases [106-108]. 
Thus, antiviral prophylaxis is recommended for HSV-
seropositive patients among allogeneic HSCT recipients 
and autologous HSCT recipients with a high risk of 
mucositis [3]. According to a study performed in the early 
1990s, the antibody-positive rates of HSV type 1 were 
100%, 91%, and 82% in populations aged over 30 years, 
in their 20s, and in their teens, respectively, in Korea. 
Antiviral prophylaxis is advised in most cases in this 
country [109].
A meta-analysis on studies using acyclovir to prevent 
reactivation of HSV revealed that lesions caused by 
HSV and its isolation rate were significantly decreased 
in the acyclovir group [110,111]. However, the mortality 
rate was reduced only when prophylactic antiviral 
agents were used during engraftment after allogeneic 
HSCT [111]. Recent studies using valaciclovir, which is 
more easily administered than acyclovir, reported that 
the development of HSV lesions was not significantly 
different between acyclovir and valaciclovir groups 
[112,113]. Antiviral prophylaxis is generally used until 
the completion of engraftment or the improvement of 
mucositis (approximately 30 days in most cases) [114,115].
Although varicella-zoster virus is frequently observed 
in patients undergoing anticancer therapy, it is not 
mentioned in these guidelines because it is beyond the 
scope of empirical therapy for neutropenic fever.
INITIAL ANTIBIOTIC THERAPY
Because infection proceeds rapidly and discrimination 
between the early stages of bacterial infection and 
noninfectious fever is difficult in neutropenic patients, 
empirical antibiotics should be initiated immediately after 
the development of fever in all neutropenic patients. Even 
when a fever is not present, symptoms and signs causing 
a reasonable suspicion of infection require empirical 
antibiotics, as in febrile patients.
What are the major etiological agents of neutrope-
nic fever in Korea?
14. I n contrast to western countries, Gram-negative 
bacteria are the prevailing etiological agents of 
infections in neutropenic fever patients in Korea.
15.  Adjustment of empirical antibiotics may be necessary 
depending on the resistance patterns in each hospital 
because the reported antimicrobial resistance rates of 
the bacteria causing neutropenic fever vary widely by 
hospital. 
The distribution of etiological agents of neutropenic 
fever in studies published in Korea over the last 10 
years is shown in Table 3. While Gram-positive bacteria 
account for 60-70% of microbiologically documented 
infection in Europe and America, Gram-negative bacteria 
were more frequently observed in studies in Korea until 
the early 2000s. This is a general characteristic in the 
Asia-Pacific region, including China, Taiwan, Thailand, 
and Malaysia [19]. Among Gram-positive bacteria, 
Streptococcus and coagulase-negative Staphylococcus 
are the most frequently observed, and Staphylococcus 
aureus and Enterococcus are next. Among Gram-negative 
bacteria, Escherichia coli is found most frequently, and 
Pseudomonas aeruginosa and Klebsiella pneumoniae 
follow it.
Little data regarding antimicrobial susceptibility to 
etiological agents has been reported in Korea, and the 
reported resistance rates vary. The rate of methicillin-
resistant S. aureus (MRSA) and those of fluoroquinolone-
resistant and third-generation cephalosporin-resistant E. 
coli were 38-77%, 16-93%, and 0-7.0%, respectively [116-
118]. Thus, each hospital needs to choose early empirical 
antibacterial agents by considering the types of frequently 
detected bacteria and their susceptibilities. For example, 
ciprofloxacin combination therapy is difficult to use as an 
early empirical antibacterial agent in hospitals showing 
a high f luoroquinolone resistance rate. Additionally, 
these guidelines do not recommend glycopeptides as 
early empirical antibacterial agents, but their partial use 
can be considered in hospitals with high MRSA rates. 
These guidelines describe general recommendations, and 
antibacterial agents not mentioned in these guidelines can 
also be empirically used according to types of detected 
bacteria and their susceptibilities in each hospital.
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Outpatient oral antibiotics
When should oral antibiotics be used as the initial 
treatment for febrile neutropenic patients?
16.  Oral antibiotics may be used for the initial treatment 
of febrile neutropenic patients if the risk of infectious 
complications is low (A-I). 
Many randomized controlled studies have demonstrated 
that febrile neutropenic patients with low risks of 
complications may be treated with oral antibiotics [122-
125]. Thus, if the risk of infectious complications is low, 
based on the risk index, oral antibiotics can be used for 
treatment. However, a survey conducted in Korea from 
2005 to 2006 found that oral antibiotics were rarely used 
for the treatment of febrile neutropenic patients in Korea 
[29].
Outpatient treatments can be considered when febrile 
neutropenic patients meet the following conditions: a fever 
does not begin during the hospital stay, acute diseases 
are not associated, neutropenia is expected to improve 
within 7 days, the general condition is good (ECOG 0-1), 
the serum creatinine level is less than 2.0 mg/dL, the liver 
function level is within 3 times the normal range, and the 
MASCC risk index is 21 points or more [3]. Additionally, 
access to a medical institution needs to be secured for 
patients to ensure early outpatient treatment.
Which oral antibiotics can be used empirically for the 
initial treatment of febrile neutropenic patients?
17.   The combination of ciprofloxacin and amoxicillin/
clavulanic acid is recommended as oral antibiotics for 
febrile neutropenic patients (A-I).
18.  The combination of ciprofloxacin and clindamycin 
is an acceptable alternative as oral antibiotics for 
penicillin-allergic patients (A-II). 
Table 3. Distribution of bacterial organisms in patients with neutropenic fever in Korea
Reference Rho et al. [119] Rhee et al. [120] Choi et al. [116] Kim et al. [121] Park et al. [118]
Period 1996-2001 1996-2003 1998-1999 1999-2000 2001-2002
Hospital A B C D C
Patients leukemia Allo-HSCT Acute leukemia Cancer HSCT
Prophylaxis NA Cotrimoxazole,
nystatin gargle
Ciprofloxacin, 
roxithromycin, 
fluconazole
NA Ciprofloxacin, 
fluconazole/ 
itraconazole,
SMX/TMP
No. of MDI 27 (100) 78 (100) 158 (100) 42 (100)  72 (100)
Gram (+) bacteria  11 (40.7)   36 (46.2)   75 (47.5)  11 (26.2)  25 (34.7)
Streptococcus  1 (3.7) -    24 (15.2)  2 (4.8)    9 (12.5)
CoNS    4 (14.8)  15 (19.2)    20 (12.7)  4 (9.5)  7 (9.7)
Staphylococcus aureus    4 (14.8) -  13 (8.2)  3 (7.1)  2 (2.8)
Enterococcus  2 (7.4) -  14 (8.9)  2 (4.8)  6 (8.3)
Gram (-) bacteria  16 (59.3)   42 (53.8)    83 (52.5)  31 (73.8)   47 (65.3)
Escherichia coli    4 (14.8) -   43 (27.2)  2 (4.8)  32 (44.4)
Pseudomonas aeruginosa  1 (3.7) -  12 (7.6)   5 (11.9)  4 (5.6)
Klebsiella pneumoniae    6 (22.2) -  12 (7.6)    8 (19.0)  4 (5.6)
Enterobacter - -    5 (3.2)  4 (9.5)  3 (4.2)
Acinetobacter baumanii  2 (7.4) - -  2 (4.8)  2 (2.8)
Aeromonas hydrophila  1 (3.7) -    6 (3.8) - -
Citrobacter freundii - - -  2 (4.8)  1 (1.4)
Salmonella - - -  4 (9.5) -
Values are presented as number (%).
HSCT, hematopoietic stem cell transplantation; NA, not available; SMX/TMP, sulfamethoxazole/trimethoprim; MdI, microbiologically 
defined infection; CoNS, coagulase-negative Staphylococcus.
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19.  However, ciprofloxacin-based oral antibiotic regimens 
are not recommended for patients recently treated 
with fluoroquinolone prophylaxis (B-II).
Well-designed randomized studies have demonstrated 
that the combination of ciprofloxacin and amoxicillin/
clavulanic acid was effective as empirical oral antibiotic 
therapy in febrile neutropenic patients in the low-risk 
group [122,124]. Penicillin-allergic patients can be treated 
with a combination of ciprofloxacin and clindamycin [126]. 
A randomized study found that ofloxacin was also effective 
in low-risk febrile neutropenic patients [125]. Levofloxacin 
was also estimated to have similar effects. Additionally, 
there are some reports that moxifloxacin can be effective 
in low-risk patients [127].
Although some small studies reported that ciprofloxacin 
monotherapy was acceptable [128,129], it has also been 
associated with the risk of serious infection caused by 
viridans streptococci and thus should be used carefully 
[130]. Fluoroquinolone-based oral antibiotic therapy is 
not recommended if fluoroquinolones have been used for 
antibiotic prophylaxis.
There are almost no studies on other oral antibiotics, 
such as cephalosporins, for the initial treatment of 
neutropenic fever, but they can be used according 
to frequently reported etiological bacteria and their 
susceptibilities. If the etiological bacteria are determined, 
various oral antibiotics can be appropriately used, based 
on their antimicrobial susceptibilities.
Intravenous antibiotics
Empirical antibiotics as initial therapy should be 
chosen by considering the susceptibilities of the bacteria 
detected in each hospital. For hospitals with high rates 
of resistant bacteria, such as MRSA and multiple-drug-
resistant Gram-negative bacteria, appropriate antibiotics 
should be used based on the circumstances in each 
hospital. Additionally, these guidelines suggest generally 
recommended antibiotics, and antibiotics not mentioned 
in these guidelines can also be used properly if their effects 
are demonstrated.
Use of antibiotics against Pseudomonas is commonly 
recommended as an initial empirical antibiotic therapy. 
Other factors that should be considered in choosing initial 
empirical antibiotics for febrile neutropenic patients 
include the infection site (s), history of MRSA infection 
or colonization, organ dysfunction, history of the use of 
antibiotics, and bactericidal effects of antibiotics.
Which intravenous antibiotics can be used as the ini‑
tial monotherapy for febrile neutropenic patients?
20.  Cefepime, imipenem/cilastatin, meropenem, or 
piperacillin/tazobactam is recommended as empirical 
monotherapy if the febrile neutropenic patient has no 
complications of infection (A-I).
21.  Ceftazidime can be considered as empiric 
monotherapy if the febrile neutropenic patient has 
no complications of infection, but clinicians should be 
aware of the possibility of breakthrough infections 
(from Gram-positive bacteria or drug-resistant Gram-
negative bacteria) (B-II).
No significant difference between antibiotic mono-
therapy and antibiotic combination therapy has been 
observed in febrile neutropenic patients without complica-
tions of infection in many randomized studies [131-140]. 
Antibiotics recommended for antibiotic monotherapy 
are cefepime, ceftazidime, imipenem/cilastatin, merope-
nem, and piperacillin/tazobactam [141,142]. Because 
ceftazidime is not effective against Gram-positive bacte-
ria, such as viridans streptococci or pneumococci, and is 
vulnerable to extended-spectrum β-lactamase and type 1 
β-lactamase, it should be used carefully [143]. Addition-
ally, a clinical study found that the clinical effect of ceftazi-
dime was lower than that of meropenem in cancer patients 
with neutropenic fever [144,145]. Thus, some professionals 
recommended the addition of cefazolin to ceftazidime to 
enhance the antibacterial activity against Gram-positive 
bacteria [146].
In a nationwide survey from 2005 to 2006, cefepime 
was used most frequently as a single antibacterial agent for 
neutropenic patients in Korea [29]. A recent meta-analysis 
revealed that cefepime could increase the mortality 
rate in neutropenic patients [147,148]. However, the US 
FDA found that the mortality rate of cefepime was not 
significantly different from that of the control group in an 
additional analysis. In Korea, a study compared cefepime 
monotherapy and ceftazidime + tobramycin combination 
therapy in 90 solid cancer patients with neutropenic 
fever; no significant difference was found in effects or 
complications between the two groups [149]. Moreover, 
a comparison between cefepime and ceftazidime 
monotherapy in 40 Koreans with cancer associated with 
neutropenic fever found no significant difference in the 
treatment success rate [150].
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Because cefepime and ceftazidime can be used without 
dose adjustment in cases of mild or intermediate renal 
inadequacy, they are relatively safe for patients taking other 
drugs to treat renal toxicity. Aminoglycoside monotherapy 
is not generally recommended as an initial antibacterial 
monotherapy for febrile neutropenic patients [2].
Other antibiotics can be added to antibacterial 
monotherapy regimens according to clinical outcomes; 
thus, clinical responses to antibiotics, secondary infection, 
adverse reactions, and resistant bacteria should be 
evaluated carefully.
Which intravenous antibiotics (with the exception of 
glycopeptides) can be used as the initial combination 
therapy for febrile neutropenic patients?
22.  An aminoglycoside + anti-pseudomonal penicillin 
(± β-lactamase inhibitor), or ciprofloxacin + anti-
pseudomonal penicillin are recommended as the 
initial intravenous combination therapy for febrile 
neutropenic patients (A-I).
23.  An aminoglycoside + an extended-spectrum 
cephalosporin (cefepime or ceftazidime) is also 
recommended as the initial intravenous combination 
therapy for febrile neutropenic patients (A-II).
Empirical combination therapy using an aminoglycoside 
and anti-pseudomonal β-lactam antibiotic (ticarcillin/
clavulanic acid, piperacillin/tazobactam, ceftazidime, 
or cefepime), with the exception of glycopeptides, is 
recommended. A combination of a fluoroquinolone and 
anti-pseudomonal β-lactam antibiotic can be administered 
to patients not treated with prophylactic fluoroquinolones 
[151-155].
According to a survey in Korea, the most common antibiotic 
combination therapy for neutropenic patients was the 
combination of a third- or fourth-generation cephalosporin 
(ceftazidime or cefepime) and an aminoglycoside [29]. 
However, inclusion of an aminoglycoside can increase 
adverse reactions, such as renal toxicity, ototoxicity, and 
hypokalemia. Taking an aminoglycoside once daily is 
an alternative to maintain its therapeutic effect and to 
help reduce these adverse events [156,157]. However, 
for treatment of meningoencephalitis or endocarditis, 
administration of an aminoglycoside once per day is not 
recommended. When a patient has poor renal function, 
it is necessary to measure the blood aminoglycoside level 
and maintain it at an appropriate therapeutic level.
In cases associated with resistant bacteria or complications, 
such as hypotension, combination therapy, rather than 
monotherapy, is recommended. In particular, clinically 
unstable febrile neutropenic patients with hypotension, 
tachypnea, newly developed or deteriorating tachycardia, 
changes in consciousness, decreased urine amounts, 
or organ dysfunction may require a combination of 
broad-spectrum β-lactam antibiotics (imipenem/
cilastatin, meropenem, or piperacillin/tazobactam) and 
an aminoglycoside to extend the antibacterial spectrum 
and to obtain an synergistic effect against some Gram-
negative bacteria. A study in Korea found that in 35 febrile 
neutropenic patients with shock, the most frequently 
observed etiological microorganism was Gram-negative 
bacteria (27 subjects, 77%); of these, E. coli was the most 
common [158]. Fig. 1 presents the algorithm for the initial 
management of febrile neutropenic patients.
RE-EVALUATION AFTER 3-5 DAYS AND 
CHANGE OF ANTIBIOTICS
To evaluate the effect of initial antibiotics, 3-5 days 
are needed [159]. At this time, future treatments are 
determined according to whether the patient has 
bacteremia or pneumonia, whether fever has improved, 
or whether the condition of the patient has deteriorated. 
If a patient’s condition deteriorates within 3 days, the 
evaluation of empirical antibiotics can be advanced. 
However, because many studies have suggested that the 
period to defervescence in febrile neutropenic patients 
is 2-7 days (median 5 days), we can wait until 5 days 
have passed without changing the initial antibiotics if a 
bacterium is not grown in cultures and fever continues to 
be observed.
Patients without fever in 3-5 days
What should be done when initial empirical antibiotics 
are effective within 3‑5 days?
24.  If the causative organism is not found and initial 
empirical antibiotics seem to be effective after 
3-5 days, the initial empirical antibiotics should be 
maintained until neutrophil recovery (A-II).
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25.  Maintain intravenous antibiotics until absolute 
neutrophil count recovery for patients who were 
in the high-risk group at the beginning of the 
administration of empirical antibiotics. For those in the 
low-risk group, consider changing to oral antibiotics 
(B-II).
When a patient’s fever improves, symptoms and signs of 
infection are stable or improved, and hemodynamic levels 
such as blood pressure or pulse rates are stable, the initial 
antibiotics are considered to be effective [3]. Under the 
circumstances, if a causative organism is identified, more 
appropriate antibiotics can be used to decrease adverse 
reactions and treatment costs. However, to prevent newly 
developed bacteremia, it is recommended to maintain a 
broad antibacterial spectrum [2]. Antibiotics should be 
maintained for at least 7 days, and it is recommended 
to continue treatment until the causative organism is 
removed in cultures, until infections of all sites are cured, 
or until symptoms and signs in the patient are eliminated. 
Changing to oral antibiotics after intravenous antibiotics 
for the first 72 hours can be considered. A study in Korea 
reported that when ciprofloxacin was orally administered 
to 40 patients showing no clear evidence of infection, an 
increasing absolute neutrophil count and defervescence in 
72 hours indicated successful treatment in 39 cases (98%) 
[160].
Although it is desirable to discontinue antibiotics after 
the recovery of neutrophils to an absolute count of > 500/
mm3, the discontinuance of antibiotics can be considered 
even in the cases of absolute neutrophil counts of < 500/
mm3 if neutropenia is maintained without symptoms or 
signs of infection. However, this approach is available only 
when a patient can be monitored carefully, the mucous 
membranes and skin are normal (no inflammation of 
the mucous membranes, ulcers, evidence of catheter 
site infections, or hemorrhage), and neither invasive 
intervention nor anticancer therapy has been planned [2].
If fever is eliminated after 3-5 days but etiological 
bacteria are not identified, it is generally recommended 
to maintain the initial antibiotics until the recovery 
of neutrophils to an absolute count of > 500/mm3. In 
cases with specific infection sites, the administration of 
antibiotics for an appropriate period based on the site 
is recommended. However, if there is no clear infection 
(pneumonia, enteritis, endocarditis, catheter-related 
infection, or skin or soft tissues infection) or no cultured 
bacteria, and if a patient is in the low-risk group at the 
beginning of the therapy, intravenous antibiotics for over 
2 days can be replaced with oral antibiotics if clinically 
necessary [122,124]. However, patients in the high-risk 
group should continue intravenous antibiotics (Fig. 2).
Patients with fever in 3-5 days
When fever persists even after 3-5 days of antibiotic 
therapy and neither infection sites nor causative organisms 
are detected, reasons shown in Table 4 can be considered. 
Re-evaluation of the following is necessary: complete 
blood cell count, general chemistry, electrolyte test, 
C-reactive protein (CRP), urinalysis, results of all cultures, 
a close physical examination, chest X-ray, evaluation 
of any vascular catheter, additional cultures of blood 
and specimens from specific infection site (s), imaging 
studies on sites suspected to have infection (if possible), 
blood antibiotic levels (particularly aminoglycosides), 
and ultrasonography or CT for patients with pneumonia, 
paranasal sinusitis, or enteritis.
The current blood culture system can detect 90-100% of 
bacteria in blood within 48 hours of blood culture. Thus, 
it is recommended to repeat blood cultures at 48-hour 
intervals, as necessary.
Neutropenic fever
Reassess after 3-5 days
Low risk
P.O. I.V.
High risk
Glycopeptide
not needed
Glycopeptide
needed
Ciprofloxacin
+
Amoxicillin
/clavulanic acid
Monotherapy
• Piperacillin/
  tazobactam
• Cefepime
• Imipenem/cilastatin
• Meropenem
• Ceftazidime
Two drugs
• Aminoglycoside +
anti-pseudomonal
  penicillin
  (± β-lactamase
  inhibitor),
cefepime
  ceftazidime
• Ciprofloxacin + 
  anti-pseudomonal
  penicillin
Glycopeptide
+
Piperacillin/tazobactam,
Cefepime,
lmipenem/cilastatin,
Meropenem,
Ceftazidime,
±
Aminoglycoside,
Ciprofloxacin
Figure 1. Algorithm for initial management of febrile neutrope-
nic patients.
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What should be done if fever persists after 3‑5 days?
26.  If fever persists after 3-5 days of antibiotic therapy 
and reassessment does not yield a cause, continue 
administration of the same antibiotics when the 
patient’s condition is clinically stable (B-II).
27.  However, if the patient is in an unstable condition, 
consider expanding the antibacterial spectrum to 
cover anaerobes, drug-resistant Gram-negative 
bacteria, or drug-resistant Gram-positive bacteria (B-
II).
28.  If the fever persists even after the use of empirical 
antibacterials, consider using antifungal agents, 
depending on the risk of infection (A-II).
If fever persists even after 3-5 days of the initial 
antibiotic therapy and its cause is not identified, one of 
following three measures can be taken (Fig. 3). First, if 
the condition of a patient is not unstable and no additional 
relevant information is obtained from re-evaluation, the 
initial antibiotics can continue to be administered. In 
particular, for patients who are expected to show recovery 
of neutrophils within 5 days, it may be appropriate to 
maintain the initial antibiotics. It is not recommended to 
change antibiotics when fever persists in a patient in stable 
condition.
Second, antibiotics can be changed or added. When a 
disease proceeds or complications or adverse drug reactions 
are observed with newly found or deteriorating abdominal 
pain or lesions of the mucous membranes, infection around 
a catheter, or changed mucous membrane flora, changing 
the initial antibiotics or adding another antibiotic should be 
considered. For these cases, cooperation with the infectious 
diseases specialists is recommended [3].
Third, antifungal agents can be added while changing or 
maintaining antibacterials. Generally, if fever persists after 
several days of empirical antibacterial use, it is necessary 
to consider the use of antifungal agents (see EMPIRICAL 
ANTIFUNGAL THERAPY section for details).
USE OF GLYCOPEPTIDES
Should glycopeptides be included in an empirical 
antibiotic regimen?
29.  Glycopeptides should not be routinely added to an 
initial empirical antibiotic regimen (A-I).
Eighteen randomized studies have investigated whether 
glycopeptides should be added to an initial empirical 
antibiotic regimen. Of them, only two were double-blind 
randomized trials [17]. The largest was a multi-center 
study that included 747 subjects [161], and the smallest 
had only 46 subjects [162]. When the 747 neutropenic 
patients in the largest study were randomly divided into 
addition of vancomycin to ceftazidime + amikacin and 
no-addition groups, the vancomycin addition group 
showed faster responses in patients who were found 
to have bacteremia caused by Gram-positive bacteria; 
however, the addition group was not significantly different 
in terms of defervescence and mortality rate compared with 
the no-addition group. Furthermore, no patient died in the 
first 3 days among the patients with bacteremia caused by 
Gram-positive bacteria. However, renal toxicity following 
Table 4. Reasons for persistent fever 3-5 days after 
initiating antibiotic therapy
Reason
Nonbacterial infection (fungal, viral, or mycobacterial infection)
Resistance to antibiotics
Inadequate drug concentration
Drug fever
Bacteremia due to cell wall-deficient bacteria
Infection at an avascular site (such as an abscess)
Fever related to underlying malignancy
Intravascular catheter-related fever
Afebrile with first 3-5 days of treatment
No etiology identified Etiology identified
Low
risk
High
risk
Discharge
• Continue same
antibiotics
• Continue same
antibiotics
or
• Change to:
Ciprofloxacin
+
Amoxicillin
/clavulanic acid
Adjust to most
appropriate
treatment
(but, maintain 
broad spectrum
antibiotics)
Figure 2. Algorithm for management of patients who become 
febrile in the first 3-5 days of initial antibiotic therapy.
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the use of antibiotics occurred in 2% of patients in the no-
vancomycin group, but was significantly higher (6%) in the 
vancomycin group (p = 0.02) [161]. Recently, the results of 
two meta-analyses on the need for the administration of 
vancomycin as an initial empirical antibiotic regimen were 
reported [163,164]. One meta-analysis examined a total 
of 2413 patients by including 14 of 18 randomized studies 
[163]. It revealed that the addition of a glycopeptide did 
not significantly reduce the total mortality rate (odds ratio 
[OR], 0.67; 95% CI, 0.42 to 1.05). In particular, an analysis 
of 405 patients that included only six studies using the 
same broad-spectrum antibiotic showed the same finding 
(OR, 1.05; 95% CI, 0.52 to 2.00). The other meta-analysis 
investigated a total of 2392 patients by including 13 
randomized studies [164]. It also found that the additional 
administration of a glycopeptide did not significantly 
decrease the total mortality rate (RR, 0.96; 95% CI, 
0.58 to 1.26). For breakthrough infection, the first meta-
analysis did not show any significant association with the 
use of glycopeptides with an OR of 1.18 (95% CI, 0.81 to 
1.98) [163], while the second one found that breakthrough 
infection caused by Gram-positive bacteria was reduced, 
with a RR of 0.28 (95% CI, 0.11 to 0.37) [164]. However, 
these findings should be interpreted carefully. All of the 
studies in the analysis were conducted from 1985 to 1993, 
before the emergence of vancomycin-resistant enterococci 
(VRE); thus, VRE breakthrough infection during the 
administration of vancomycin was not reflected [17]. 
Moreover, because viridans streptococci bacteremia can 
deteriorate rapidly, to streptococcal toxic shock syndrome, 
in neutropenic patients, there is a suggestion that the 
addition of vancomycin to an initial antibiotic regimen 
is favorable in hospitals with high penicillin resistance 
of viridans streptococci [165]. However, most β-lactam 
antibiotics (e.g., cefepime, imipenem/cilastatin, meropenem, 
piperacillin/tazobactam), except ceftazidime, have good 
antibacterial activity against viridans streptococci, so 
vancomycin is not likely to be of additional help unless 
ceftazidime monotherapy is used [166].
Although the frequencies of MRSA and VRE are 
high in Korea, there has been no randomized study 
on this issue. Only one retrospective study on MRSA 
bacteremia in not only neutropenic patients, but also 
others, reported that the addition of vancomycin to an 
initial antibiotic regimen did not significantly affect the 
prognosis [167]. According to data from an analysis of 457 
Persistent fever at days 3-5
Re-assess: CBC, chemistry, cultures, fungal serology, CRP, radiography, imaging study
If no change in 
patient’s condition
Previous
monotherapy
Continue initial
antibiotics
Add aminoglycoside:
Consider changing to another monotherapy
Consider changing β-Iactam
and/or
Fungus study
Fungal culture +
Febrile
Re-assess at 48 hr
Afebrile
No change
Possible/probable
fungal infection
Add antifungal
agent
Specific
therapy
Previous
combination therapy
If progressive
disease
Etiology established
Adjust; If Gram-positive,
consider a glycopeptide
Etiology unknown
Figure 3. Algorithm for management of patients who have a persistent fever after 3-5 days of initial antibiotic therapy. CBC, complete 
blood count; CRP, C-reactive protein.
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febrile neutropenic patients in a university hospital for 
10 years [158], S. aureus was identified in 10 (6%) of 172 
patients with proven bacteremia, and 77% of them had 
MRSA. Although data on the rate of viridans streptococci 
bacteremia in febrile neutropenic patients are insufficient 
in Korea, approximately 5-7% of the total bacteremia was 
reported to show viridans streptococci [117,158]. The data 
on penicillin-resistance of viridans streptococci are also 
insufficient. One study reported that with the exception 
of pneumococcus isolated from neutropenic patients, 7 
(36%) of 19 streptococci strains were penicillin-resistant 
[116]. While some researchers have reported that the 
antimicrobial susceptibility tests of 103 strains of viridans 
streptococci isolated from various clinical specimens in a 
university hospital found no penicillin resistance (although 
they were not from neutropenic patients) [158,168], others 
have insisted that of 45 strains isolated from blood, 27% 
were not susceptible to penicillin [169].
However, S. aureus bacteremia is rarely found as a 
causative organism of bacteremia for the first fever in 
neutropenic cancer patients after cytotoxic chemotherapy. 
Its rate was reportedly 1-2% in large-scale clinical 
studies [132,138,144]. Furthermore, the frequency of 
resistant bacteria, such as MRSA, is low for the first 
fever; bacteremia caused by Gram-positive bacteria does 
not deteriorate rapidly in cases of late initial treatment, 
unlike bacteremia caused by Gram-negative bacteria, 
and indiscriminate use of glycopeptides can lead to the 
emergence of resistant bacteria and nephrotoxicity. 
Thus, there is insufficient evidence to support the 
routine inclusion of glycopeptides in the initial antibiotic 
therapy for febrile neutropenic patients in Korea. Based 
on these findings, it is recommended not to routinely 
add vancomycin to the treatment regimen for febrile 
neutropenic patients in whom the cause has not been 
clearly determined (A-I).
30.  When fever persists or recurs 3-5 days after the 
initiation of the empirical treatment, glycopeptides 
should not be routinely added to the empirical 
treatment (B-I).
Two randomized studies investigated whether the 
addition of a glycopeptide was effective if fever persisted 
for 3-4 days after beginning initial antibiotic therapy 
[170,171]. One study randomly administered vancomycin 
or placebo to 165 of 763 patients whose fever had not 
improved within 3-4 days after the empirical use of 
piperacillin/tazobactam. The two groups were not 
significantly different in terms of defervescence, mortality 
rate, breakthrough infection, or the frequency of the use 
of amphotericin B deoxycholate [170]. This result was 
consistent with that of a recent meta-analysis (RR of 
treatment failure, 0.61; 95% CI, 0.18 to 2.09) [164]. Based 
on these findings, it is recommended not to routinely add 
glycopeptides when fever persists or recurs after 3-5 days 
(B-I).
31.  The use of glycopeptides as empirical antimicrobial 
therapy is recommended if the patient’s blood 
cultures are positive for Gram-positive bacteria, 
a catheter-related infection is suspected, there 
is colonization with MRSA or a history of MRSA 
infection, the patient has severe sepsis or shock 
pending the results of cultures, or the patient has a 
skin or soft tissue infection (A-II).
Studies on the detailed indications of glycopeptides as 
an initial empirical antibiotic regimen are not sufficient, 
but the indications consistently suggested by most 
specialists, including those who contributed to the IDSA 
and NCCN guidelines, are as follows:
1.  Positive for Gram-positive bacteria in blood culture (A-
II)
2. Suspected catheter-related infection (A-II)
3.  History of MRSA and penicillin-resistant S. pneumoniae 
colonization or infection (A-II)
4.  Severe sepsis or shock following sepsis (A-II)
5.   Skin or soft tissue infection (A-II)
The following indications remain controversial among 
specialists:
1.  Risk of viridans streptococci bacteremia (B-III)
2.  Severe damage to the mucous membrane due to 
anticancer therapy (B-III)
3.  Prophylaxis using sulfamethoxazole/trimethoprim or 
fluoroquinolone (B-III)
However, even after glycopeptides are administered 
according to the indications, the discontinuance of 
glycopeptides is recommended if bacteremia caused by 
resistant Gram-positive bacteria is not observed in blood 
cultures (A-I).
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Are the efficacy and the adverse reactions of 
teicoplanin identical to those of vancomycin when 
a glycopeptide is used as an empirical antibiotic. 
regimen for neutropenic patients?
32.  The use of teicoplanin can be considered as empirical 
antibiotic therapy for neutropenic patients because it 
has equivalent efficacy and lower adverse reactions, 
such as nephrotoxicity, compared with vancomycin 
(B-I).
As of 2009, 18 randomized studies comparing the 
efficacy and adverse reactions of teicoplanin and 
vancomycin had been reported. Of these studies, 13 were 
performed with neutropenic patients. A meta-analysis 
on these randomized studies revealed that the mortality 
rates (RR, 0.95; 95% CI, 0.74 to 1.21) and clinical failures 
(RR, 0.92; 95% CI, 0.81 to 1.05) were not significantly 
different between teicoplanin and vancomycin [172]. 
Additionally, an analysis limited to the studies conducted 
in neutropenic patients found no statistically significant 
difference in the mortality rates (RR, 0.95; 95% CI, 0.68 
to 1.34) or clinical failures (RR, 0.98; 95% CI, 0.83 to 1.16) 
between teicoplanin and vancomycin [172]. However, 
fewer adverse reactions were observed in the teicoplanin 
group compared with the vancomycin group (RR, 0.61; 
95% CI, 0.50 to 0.74). In particular, nephrotoxicity was 
lower in the teicoplanin group than in the vancomycin 
group (RR, 0.44; 95% CI, 0.32 to 0.61) [172]. However, 
teicoplanin is not yet approved by the US FDA as an 
empirical antibiotic for MRSA infection and neutropenia, 
and clinical experience and research data on it in severe 
infections (e.g., endocarditis and encephalomeningitis) 
are not sufficient compared with those for vancomycin. 
Moreover, previous randomized studies did not include 
many patients with MRSA infection itself [172]. As the 
minimum inhibitory concentration (MIC) of vancomycin 
against S. aureus has risen, treatment failures have been 
reported [173], and the vancomycin MIC and levels need to 
be measured in some cases. Data regarding the association 
between teicoplanin MIC and treatment failure are 
insufficient, and levels are difficult to examine; thus, it 
should be used carefully. Additionally, most studies have 
stated that the efficacy of teicoplanin was identical to that 
of vancomycin by taking it once daily after a loading dose 
[172], but some researchers recommend administering 
a high dose for infections with complications. Thus, the 
appropriate dose remains controversial [174].
DISCONTINUATION OF ANTIBIOTICS
When can antibiotic therapy be discontinued?
33.  If the origin of the fever is unclear, it is recommended 
to continue antimicrobials until the absolute 
neutrophil count reaches 500/mm3 or higher (A-II).
34. I f the causative organism or infection site has been 
identified, treatment duration is adjusted to the 
specific infectious disease in line with the recovery of 
neutrophils (A-II).
Duration of antibiotic therapy should be determined 
by considering the infection site, causative organism, 
general condition of the patient, treatment response, 
and neutrophil recovery [3]. If the origin of fever is 
unclear, antimicrobials should be maintained until the 
absolute neutrophil count reaches 500/mm3 or higher 
[3]. When the causative organism or the infection site has 
been identified, treatment duration should be adjusted 
to the specific infectious disease by considering the 
neutrophil recovery [3]. Because there is insufficient 
evidence regarding treatment duration for these 
clinical circumstances, this committee suggests general 
recommendations.
If the cause of fever is unclear
When the absolute neutrophil count is over 500/mm3, 
the fever has improved, and the patient is in a clinically 
stable condition, empirical antibiotic therapy should 
be discontinued (A-II). If the absolute neutrophil count 
is over 500/mm3, fever is persistent, and the patient is 
clinically stable, then the patient should be monitored for 
approximately 5 days and empirical antibiotic therapy 
should be discontinued for a differntial diagnosis (e.g., 
drug fever, hepatosplenic candidiasis). If the absolute 
neutrophil count is less than 500/mm3 but the fever has 
improved and the patient is in a clinically stable condition, 
antibiotic therapy should be continued until neutrophil 
recovery (A-II). Patients in the low-risk group can be 
changed to oral antibiotics and therapy can be maintained 
until recovery of the absolute neutrophil count to over 
500/mm3 occurs (A-II). However, some experts say that 
for a clinically stable patient whose absolute neutrophil 
count is expected not to recover, the cause of fever is 
not clear, and the fever does not persist for more than 
7-14 days, empirical antibiotic therapy can be discontinued 
carefully (B-III).
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If the cause of infection is identified microbiologically 
or clinically
For a microbiologically or clinically documented 
infection, antibiotic therapy for the treatment duration of a 
specific infection should be conducted as shown in Table 5.
CATHETER-RELATED INFECTIONS
Which examination is useful in the diagnosis of 
catheter-related infection?
35.  If a catheter-related infection is suspected, a skin swab 
for culture from the exit site of the catheter and blood 
cultures from the catheter may be obtained (B-II).
36.  The differential time to positivity is a useful diagnostic 
tool for detecting catheter-related infection (A-II).
Catheter-related infection is a common complication 
frequently observed in neutropenic patients [3]. Exit-site 
infection is defined as a local flare or induration within 2 
cm of the exit of a catheter and tunnel infection is defined 
as a local flare or induration > 2 cm from the exit of a 
catheter, pus from the exit, or a local flare or induration 
along the tunnel [175]. If catheter-related infection is 
suspected, a skin swab for culture from the exit of the 
catheter should be obtained, and blood cultures from the 
catheter itself should be conducted [3]. Because the skin 
swab culture from the exit site has a low specificity for 
catheter-related infection, but shows a high sensitivity, 
it can be useful for the exclusion of certain diagnoses 
[176]. Additionally, a study reported that blood cultures 
from both central venous catheters and peripheral blood, 
when performed by the automated blood culture systems 
used by many hospitals, could also measure the time for 
bacteria to grow initially. Furthermore, the differential 
time to positivity (DTP) or the difference between the 
two times was helpful for the diagnosis of catheter-
related infection [3]. That is, when > 120 min of DTP was 
designated as a cutoff value, its sensitivity and specificity 
were high for the diagnosis of long-term catheter-related 
infection in recent studies [177-181]. However, because the 
studies were not performed with long-term catheters, such 
as the Hickman catheter, and because the specificity of the 
examination was lower for patients already treated with 
antibiotics, the results should be interpreted carefully.
Most catheter-related infections are caused by Gram-
positive bacteria, and coagulase-negative Staphylococcus 
is most frequently isolated [182]. Thus, if catheter-related 
infection is clinically suspected, a glycopeptide, such as 
vancomycin, can be used (A-II). Because linezolid was 
found to increase the mortality rate when it was routinely 
administered to patients with suspected catheter-related 
infection in a randomized trial [183], it is not routinely 
recommended for the treatment of suspected catheter-
related infection except in patients with catheter-related 
infection confirmed to have been caused by Gram-positive 
bacteria (A-I).
When should a catheter be removed? 
37.   Catheter removal is recommended for patients 
with bloodstream infections caused by fungi, 
non-tuberculous mycobacteria, Bacillus spp., 
Corynebacterium jeikeium, S. aureus, Acinetobacter, 
P. aeruginosa, Stenotrophomonas maltophilia, and 
vancomycin-resistant Enterococcus (A-II).
38.  If the catheter has not been removed because the 
presence of a catheter-related infection is clinically 
uncertain, catheter removal may be considered if the 
same bacteria are identified in the consecutive blood 
culture at 48 72 hours after beginning appropriate 
antibacterial agents (B-II). However, immediate 
removal of the catheter is necessary if a catheter-
related infection is suspected and the patient is 
clinically unstable (A-II).
Most catheter-related infections can be improved by 
Table 5. Suggested duration of therapy for documented 
infection
Microbiologic or clinically documented infection
Skin and soft tissue infection: 7-14 days 
 (if Gram-negative sepsis, consider 10-14 days)
Bacteremia
 Gram-positive bacteria: 7-14 days
 Gram-negative bacteria: 10-14 days
 Staphylococcus aureus: at least 2 weeks after first negative    
  blood culture or 4-6 weeks
  Yeast: at least 2 weeks after first negative blood culture
Sinusitis: 10-21 days
Bacterial pneumonia: 10-21 days
Intra-abdominal infection (i.e., typhlitis): until no evidence of symp-
  toms or signs of infection and neutrophil recovery
HSV/VZV: 7-10 days
HSV, herpes simplex virus; VZV, varicella-zoster virus.
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antibiotic therapy without removal of the catheter [3]. In 
particular, the catheter salvage rate of coagulase-negative 
Staphylococcus reaches 70-80% with intravenous 
antibiotics alone; thus, the use of antibiotics without 
catheter removal is generally recommended [182,184] 
(A-II). However, for catheter-related infection caused by 
fungi (yeasts or molds) or non-tuberculous mycobacteria 
(e.g., Mycobacterium chelonae, M. abscessus, or M. 
fortuitum), the catheter should be removed immediately 
[3]. Bacillus spp., C. jeikeium, S. aureus, Acinetobacter, 
P. aeruginosa, S. maltophilia, and VRE can be difficult 
to treat with antibiotic therapy alone [3]. Thus, catheter-
related infections caused by these microorganisms 
also require initial catheter removal (A-II). In cases 
with severe inflammation of the mucous membranes, 
intestinal bacteria flora, such as VRE and Candida, can 
cause infection through the blood; DTP is helpful in 
discriminating these cases from those of catheter-related 
infection [3]. Moreover, when the catheter is not removed 
because the presence of catheter-related infection is 
unclear, but the same bacteria are identified in consecutive 
blood cultures 48-72 hours after beginning appropriate 
antibiotics, catheter removal should be considered [3,182] 
(B-II). However, if catheter-related infection is suspected 
and a patient is clinically unstable, the catheter requires 
immediate removal [3] (A-II). In cases of bacteremia 
caused by S. aureus, when catheter-related infection is 
suspected, catheter removal is generally recommended, 
because the success rate is low [185] (A-II). However, if 
the fever of a patient with a catheter and unclear cause of 
infection improves in 48-72 hours after beginning proper 
antibiotics and the blood culture result is negative, the 
process can be closely monitored while maintaining the 
catheter [184] (B-II). General indications for catheter 
removal are presented in Table 6.
EMPIRICAL ANTIFUNGAL THERAPY
When should empirical antifungal therapy be 
considered if empirical antibacterial agents are 
not effective?
39.  Empirical antifungal therapy is recommended in 
patients who are expected to maintain neutropenia 
for a longer period (> 10 days), when the fever 
dose not resolved within 3-5 days of initial empirical 
administration of antibacterial agents (A-II).
40.  Regardless of fever, empirical antifungal therapy 
is recommended in patients who have a history 
of invasive fungal infection, fungal colonization 
with neutropenia, symptoms (pleuritic chest pain, 
blood tinged sputum, or hemoptysis) or signs that 
suggest newly developed pneumonia, tenderness, or 
edema around the paranasal sinuses or orbital area, 
ulcerating lesions or eschar in the nose (A-II).
Empirical antifungal therapy is a standard treatment 
when broad-spectrum antibacterials are not effective 
in neutropenic fever patients, based on clinical studies 
conducted in the 1980s [2,3,11,14,186-190]. Although 
characteristics of the patients, medications, and 
epidemiology of fungi may differ compared with those 
of 20-30 years ago, a lack of antifungal therapy for 
continuous neutropenic fever can increase invasive fungal 
infection (IFI) and lead to a higher mortality rate following 
IFI. Thus, empirical antifungal therapy is recommended 
in these cases (A-II) [3,14,191].
Currently, 40-50% of neutropenic patients classified as 
high-risk are known to take empirical antifungal agents 
[190]. According to a study that analyzed patients after 
HSCT and anticancer therapy in a single center in Korea 
from March 2000 to February 2001, 122 of 318 (38.4%) 
patients used empirical antifungal agents, and 74 (23.8%) 
Table 6. Suggested indication for catheter removal
1. Tunnel infection
2. Septic phlebitis
3. Catheter-related infection caused by Candida spp.
4. Mycobacterial catheter-related infection
5. Suspected catheter-related infection and clinically unstable
6. Persistent bacteremia or clinically deteriorating 72 hr after the initiation of appropriate therapy
7. Catheter-related infection caused by Staphylococcus aureus (B-II)
8. Other Gram-positive organisms: Bacillus spp., Corynebacterium jeikeium, vancomycin-resistant enterococci
9. Gram-negative organisms such as Pseudomonas aeruginosa, Acinetobacter, Stenotrophomonas maltophilia
All of the recommendations are level A-II with the exception of recommendation 7.
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among them had IFIs that were caused by Aspergillus 
and Candida species in most cases (6, 46, and 22 proven, 
probable, and possible IFIs, respectively) [192]. A foreign 
study also stated that approximately 15-45% of patients 
with a continuous neutropenic fever were estimated to have 
IFI [190]. Other reasons that antifungal therapy is used 
before a definitive diagnosis of infection are 1) because IFI 
is difficult to diagnose during the neutropenic period, 2) 
the delay of antifungal therapy to definitive diagnosis can 
easily provoke disseminated infection, and 3) in the autopsy 
of patients who died of neutropenic fever, IFI (Candida 
or Aspergillus species in most cases) that had not been 
clinically documented was found, and a continuous fever 
was the only initial sign of IFI [14,188-190].
If fever persists or recurs even after the administration 
of antibacterials, empirical antifungal therapy should be 
conducted [2]. When to begin the empirical antifungal 
therapy can differ according to the degree of risk. Patients 
in the low-risk group do not need to start antifungal 
therapy before diagnosis, while those in the intermediate-
risk group are recommended to begin antifungal therapy 
when fever persists after 6-8 days of beginning broad-
spectrum antibacterials due to continuous neutropenic 
fever and neutropenia. For patients in the high-risk group 
with over 10 days of neutropenia, empirical antifungal 
therapy should be started quickly when neutropenic 
fever persists or recurs after 3-5 days of beginning broad-
spectrum antibacterials or when the clinical condition 
deteriorates [11,193]. When neutropenia is expected to 
persist for a relatively short period (< 10 days) or estimated 
to have been resolved for several days from the decision 
of whether to use empirical antifungal therapy, empirical 
antifungal therapy is not routinely considered, unless 
there is a symptom or sign causing suspicion of invasive 
fungal infection or a history of invasive fungal infection 
(B-III).
Which antifungal agents can be used empirically?
41.  The following antifungal agents are recommended 
or can be considered for empirical antifungal therapy: 
caspofungin (A-I), liposomal amphotericin B (A-I), 
amphotericin B deoxycholate (B-I), itraconazole (B-I), 
and voriconazole (B-II). Amphotericin B deoxycholate 
should not be considered in the presence of risk 
factors for nephrotoxicity (B-I).
42.  Azoles may not be considered as empirical antifungals 
if prophylaxis with fluconazole or itraconazole has 
already been administered (B-II).
Because many types of antifungal agents have been 
developed over the last 10 years and antifungal prophylaxis 
has been widely conducted in the high-risk group, 
filamentous fungi, as opposed to yeasts, such as Candida, 
have been found more frequently in IFIs of febrile 
neutropenic patients. Moreover, the rate of non-albicans 
species in candidiasis has increased, and f luconazole 
resistance has become a problem [193-196]. Thus, empirical 
antifungal agents need to meet the following conditions: 
1) appropriate antifungal activity (having susceptibility to 
prevalent fungi in a region and in a hospital, or at least to 
Candida and Aspergillus species), 2) acceptable results in 
randomized controlled studies, 3) recommendations in 
currently published guidelines, 4) superior tolerance and 
less adverse reactions, and 5) a reasonable price [197].
To assess the effect of empirical antifungal therapy, the 
following five composite endpoints are comprehensively 
considered: 1) resolution of fever during neutropenia, 2) 
successful treatment of any baseline fungal infection, 
3) absence of any breakthrough fungal infection during 
therapy or within 7 days after completion of therapy, 4) 
no premature discontinuation of therapy because of drug-
related toxicity or lack of efficacy, and 5) survival for 7 
days after the completion of therapy. If the therapy does 
not satisfy any of these endpoints, it is considered to be 
ineffective [198-200]. When toxicity is observed after 
initial empirical antifungal therapy, other antifungal 
agents can be used early in treatment. However, the time 
to determine whether it is effective remains a controversial 
issue. For amphotericin B deoxycholate, which is still 
widely used in Korea, it is recommended to change to 
other antifungal agents if there is no effect within 3-5 
days. When an empirical antifungal agent is changed, a 
different class of antifungals should be considered first 
(B-III).
Because amphotericin B deoxycholate has been used as 
an empirical antifungal for decades and various antifungal 
agents have since been developed, their efficacy, safety, 
and adverse reactions have been compared. In Europe and 
the US, fluconazole, itraconazole, liposomal amphotericin 
B (not amphotericin B deoxycholate), caspofungin, 
and voriconazole have been administered empirically 
(voriconazole is not used as an empirical antifungal agent 
without the approval of KFDA as of 2009) [14,29,195,201].
Recommended empirical antifungal agents are 
summarized in Table 7, including doses and characteristics.
Although amphotericin B deoxycholate has been widely 
used in Korea due to the accumulated experience with 
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its use and its broad antifungal spectrum, the rate of 
adverse reactions, such as infusion-related toxicity and 
nephrotoxicity, which is reportedly as high as 50%, is a 
limitation. ECIL-1 does not recommend amphotericin 
B deoxycholate in patients 1) with underlying renal 
impairment, 2) taking co-medications with nephrotoxicity 
(e.g., taking an immunosuppressant, such as cyclosporin 
or tacrolimus after allogeneic HSCT, or antibiotics 
with nephrotoxic potential, such as aminoglycosides), 
and 3) with a previous history of toxicity. Additionally, 
current guidelines and reports do not recommend 
amphotericin B deoxycholate as an empirical agent 
because of its low efficacy and frequent and severe adverse 
events [3,14,190,193,195,197,201]. Therefore, although 
considering the accumulated experiences with its use, 
broad-spectrum activity, and low price, this committee 
does not suggest amphotericin B deoxycholate for patients 
with underlying renal impairment, taking co-medications 
with nephrotoxicity after allogeneic HSCT, or with a risk 
of renal failure, such as the elderly (B-I).
Liposomal amphotericin B produces an effect similar 
to that of amphotericin B deoxycholate (50% vs. 49%), 
but the frequencies of proven breakthrough fungal 
infection and adverse reactions (infusion-related toxicity 
and nephrotoxicity) of the five composite endpoints 
were significantly lower for liposomal amphotericin 
B [3,14,190,198,202]. In particular, the frequencies of 
infusion-related toxicity (17% vs. 44%) and nephrotoxicity 
(19% vs. 34%) were significantly lower [198]. This 
committee recommends liposomal amphotericin B for 
antifungal therapy as A-I. 
The overall success rate of caspofungin does not differ 
from that of liposomal amphotericin B (33.9% vs. 33.7%), 
but its survival rate for > 7 days after the end of therapy 
was higher and the mortality rate in underlying fungal 
infection patients was significantly lower. Moreover, 
discontinuation of a drug due to drug-related toxicity 
and adverse reactions was observed less frequently 
for caspofungin [3,14,190,200]. Thus, this committee 
recommends caspofungin and liposomal amphotericin B of 
the same strength (A-I). However, only the intravenous type 
is available, and it is not effective against Zygomycetes or 
Cryptococcus species.
Itraconazole in capsule form shows a dif ferent 
absorption rate according to patients, and its absorption 
rate is improved in the oral and intravenous forms 
when combined with cyclodextrin. When intravenous 
itraconazole and amphotericin B deoxycholate were 
compared, they had similar efficacies and the toxicity of 
intravenous itraconazole was lower [3,14,190,203,204]. 
In a recent study, itraconazole provoked fewer adverse 
reactions and its eff icacy was superior to that of 
amphotericin B deoxycholate, but the time to response and 
the length of fever were longer [205]. However, its potential 
for drug interaction should be monitored carefully, and it 
should be particularly avoided in patients with congestive 
heart failure.
Although voriconazole shows less breakthrough 
invasive fungal infection compared with liposomal 
amphotericin B in neutropenic fever patients (p = 0.02), 
its overall success rate is lower (26% vs. 31%), “non-
inferiority” has not been proven, and it is not approved as 
an empirical antifungal agent by the FDA [3,14,190,199]. 
However, it is recommended as a primary therapeutic 
agent for aspergillosis, with a recommendation strength 
of A-I, and is used for off-label indications as an empirical 
antifungal agent due to low rates of breakthrough fungal 
infection and nephrotoxicity in the US and other countries 
[193,195,201,206]. Thus, this committee suggests the use 
of voriconazole as an empirical antifungal agent only in the 
high-risk group with a high risk of invasive aspergillosis.
Although fluconazole has been reported not to differ 
from amphotericin B deoxycholate, it has limitations as 
an empirical antifungal agent because it is not effective 
against filamentous fungi, such as Aspergillus species, 
and is used prophylactically [3,14,190,195,207]. A 
questionnaire survey conducted in HSCT centers of Korea 
reported that antifungal prophylaxis was administered to 
57.6% of anticancer therapy and 90.9% of HSCT patients 
[29]; thus, fluconazole can be used as an initial empirical 
antifungal agent for patients not undergoing antifungal 
prophylaxis and in hospitals with a high rate of Candida 
infection.
The current trend of prophylaxis with antifungal agents 
effective against filamentous fungi is thought to largely 
influence the choice of empirical antifungal agents. When 
f luconazole or itraconazole is included in antifungal 
prophylaxis, there is an opinion that it should not be 
considered an empirical antifungal agent [195]. Future 
clinical studies to determine which empirical antifungal 
agents are appropriate according to types of antifungal 
prophylaxis are expected to be performed.
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Table 7. Recommendation of empirical antifungal agents in neutropenic fever
Antifungal agents Daily dose Recommendation 
level
Comments/cautions
Caspofungin 70 mg IV × 1 dose,  
  then 50 mg IV q24h
70 mg IV × 1 dose,  
  then 35 mg IV q24h  
  for patients with moderate 
  liver disease
A-I Only echinocandin is approved as empirical therapy in 
  febrile neutropenia
Similar efficacy, but less toxic compared with liposomal 
  amphotericin B as empirical antifungal therapy for 
  persistent neutropenic fever
Rarely hepatotoxic, not nephrotoxic
Available only in IV formulation
Not active against Zygomycetes, Cryptococcus
liposomal 
amphotericin B
3 mg/kg IV q24h A-I Reduced infusion-related toxicity and nephrotoxicity 
compared with amphotericin B deoxycholate
At least as effective and safer than amphotericin B 
  deoxycholate as empirical antifungal therapy in 
  neutropenic fever
Amphotericin B 
deoxycholate
0.5-1.5 mg/kg IV q24h B-I
a
Broad spectrum of activity including Candida, 
  Aspergillus, Zygomycetes, Cryptococcus, and other 
  rare molds
Substantial infusion-related toxicity and nephrotoxicity 
  including electrolyte wasting
Itraconazole 200 mg IV q12h × 4 doses,  
  then 200 mg IV q24h
B-I Negative inotropic effects; contraindicated in patients 
  with congestive heart failure
Increases cyclophosphamide metabolites; associated 
  with hyperbilirubinemia and nephrotoxicity
Potent inhibitor of the cytochrome P450, with regard to 
  drug interaction
Not active against Zygomycetes
IV formulation should be used with caution in patients 
  with significant renal impairment
Therapeutic drug monitoring is necessary
Voriconazole 6 mg/kg IV q12h × 2 doses,  
  then 4 mg/kg IV q12h; 
  oral 200 mg PO bid daily 
  (in case of aspergillosis)
B-II Not approved by KFdA as an empirical antifungal agent 
  for neutropenic fever
Most panel members consider to be an acceptable 
  option empirically in patients at high risk for invasive 
  mold infection
Consider drug interaction (rifampin, phenobarbital, etc.)
In Asian population, 10-20% of patients are poor 
  metabolizers of voriconazole
Not active against Zygomycetes
IV formulation should be used with caution in patients 
  with significant renal impairment
Therapeutic drug monitoring is necessary
Fluconazole 400 mg IV q24h C-II Active against Candida
C. glabrata is associated with variable resistance and C. 
  krusei is always resistant
Not active against molds (e.g., Aspergillus spp., 
  Zygomycetes)
KFdA, Korea Food and drug Administration.
aPanels do not recommend amphotericin B deoxycholate in the presence of risk factors for renal toxicity (B-I) (e.g., impaired renal function 
at baseline, nephrotoxic co-medication including cyclosporin or tacrolimus in allogeneic hematopoietic stem cell transplantation recipients, 
aminoglycosides antibiotics, old age, or history of previous toxicity).
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Which additional examination(s) can be conducted 
to diagnose fungal infection after examinations 
have been performed in the early stages of fever?
43.  Periodic radiological examinations such as chest 
X-rays and CT, fungal cultures, non-culture based 
microbiological tests, such as galactomannan and 
β-D-glucan, and sputum or nasal swab surveillance 
are useful for the early diagnosis of fungal infections 
(B-I).
44.  Active efforts, such as bronchoscopy, bronchoalveolar 
lavage, tissue biopsy, and culture, are necessary (B-II).
The Mycoses Study Group of the European Organization 
for Research and Treatment of Cancer (EORTC/MSG) 
revised the definition of invasive fungal infection in 
2008 to include various methods [208]. However, the 
definitions were made for communication between 
clinical researchers, researchers of epidemiological 
studies, and clinicians, and were not an actual standard 
practice applied to patients clinically. That is, even when 
a case does not meet the definition, it does not mean 
every IFI can be excluded. As clinical characteristics and 
radiological and laboratory markers have been developed 
and repeatedly tested, they have been used to identify IFIs 
and to treat them early. These efforts enhance the survival 
rate of IFI by treating it early with only a small number 
of antifungals and reduce unnecessary use, adverse 
reactions, and medical costs by administering antifungals 
only to patients in need of them [209]. Additionally, 
regarding beginning empirical antifungal therapy, there 
are many efforts to diagnose and treat IFI early and 
to determine the treatment duration by using one or a 
combination of repeated fungal cultures, simple X-ray, CT, 
and non-culture-based diagnostic tests, even when IFI is 
not clinically suspected [209-211].
In patients with a sustained neutropenic fever, CT is 
helpful to diagnose IFI, especially invasive aspergillosis. 
The halo sign or haziness around a nodule or infiltration 
is a characteristic chest CT finding of infection caused 
by angio-invasive microorganisms, and it is useful for 
the suspicion of invasive aspergillosis observed in long-
term neutropenic patients; however, it is not found in all 
patients. Although there is no disease-specific radiological 
finding characteristic of IFI, empirical antifungal 
therapy (mold-active therapy) should begin when severe 
neutropenia persists with symptoms such as fever, cough, 
and chest pain and pulmonary nodules or infiltration are 
newly observed on CT images. Additionally, the results of 
radiological examinations (e.g., CT, MRI) of the abdomen, 
paranasal sinuses, and head and neck are considered 
in combination with patients’ symptoms and signs and 
laboratory findings. If there are any abnormalities in the 
examinations, active efforts, such as bronchoscopy and 
biopsy, are made to lead to confirmation of the diagnosis 
and to determine the appropriate use of antifungals 
through targeted therapy [2,3,12,209].
Galactomannan (GM) is a component of the cell wall 
of fungi and is used for double-sandwich enzyme-linked 
immunosorbent assays. It is examined in the plasma, 
serum, bronchoalveolar lavage fluid, and cerebrospinal 
f luid, and is known to be helpful for the diagnosis of 
invasive aspergillosis. Its sensitivity and specificity 
differ according to the study, and its cutoff value varies 
according to the type of underlying disease and antifungal 
prophylaxis [209,212-214]. When antibiotics such as 
piperacillin/tazobactam or amoxicillin/clavulanic acid 
are used, a false-positive result may be observed, and 
antifungals that are currently effective against filamentous 
fungi can provoke a false-negative result [195,213,215]. 
Except as an auxiliary measure for diagnosis, GM is 
used for surveillance in the high-risk group (for early 
diagnosis before symptoms) and monitoring of responses 
after antifungal therapy. A recent meta-analysis reported 
that the sensitivity and specificity of GM analysis were 
71% (95% CI, 68 to 74) and 89% (95% CI, 88 to 90), 
respectively [216], but a study using it clinically found that 
its sensitivity was < 50% [217]. In particular, because false-
negative results can be observed when using antifungals, 
results should be interpreted carefully.
Moreover, another component of the cell wall of fungi, 
(1→3)-β-D-glucan, is currently used as an auxiliary measure 
to diagnose IFI. Unlike GM, it is detected in not only 
Aspergillus, but also Candida, Fusarium, Trichosporon, P. 
jirovecii, Acremonium, and Saccharomyces; however, it 
has not been identified in Zygomycetes [213,215].
Although the polymerase chain reaction (PCR) method 
has been developed, it has not been standardized and 
results on clinical validity do not exist. Thus, EORTC/
MSG does not recommend it as an auxiliary measure for 
diagnosis. Despite this, real-time quantitative PCR has 
been attempted for many genera and species of fungi 
[208,213,215]. Nucleic acid sequence-based amplification 
(NASBA) that manufactures a primer with a preserved 
18S rRNA base sequence and nucleic acid and performs 
isothermal amplification has also been developed [218].
Antifungal therapy using described surrogate markers is 
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called “preemptive therapy” and has been recently studied 
[211], but this committee believes that it is too early to 
recommend it for routine preemptive therapy in Korea.
Until when should empirical antifungal therapy be 
used?
45.  Treatment duration is usually determined by 
defervescence, recovery of the absolute neutrophil 
count, and a clinically stable condition. Empirical 
antifungals may be discontinued early if defervescence 
is achieved, neutropenia has recovered, and fungi 
have not been identified. However, if invasive fungal 
infection is identified during empirical therapy, the 
proper treatment duration for the respective disease 
should be followed (B-III).
When fungal infection is confirmed during the use of 
empirical antifungal therapy, the treatment duration is 
determined by any underlying disease(s) and the type and 
spectrum of fungal infection [2,193,194]. If fungal infection 
is not confirmed, there is no accurate standard by which 
to determine the empirical treatment duration, but in 
previous studies, the duration was an average of 7-14 days 
(range, 1 to 113) [198-200,203-205]. The treatment duration 
was limited mainly to experience with amphotericin 
B deoxycholate. Amphotericin B deoxycholate may be 
discontinued when neutropenia is improved, the patient’s 
condition is stable, and there are no abnormalities on 
chest and abdominal CT. If neutropenia persists but 
the patient’s condition is clinically stable, amphotericin 
B deoxycholate can be discontinued when it has been 
used for 2 weeks and there are neither suspicious lesions 
on physical examination nor abnormalities on CT. For 
stable patients in the high-risk group, continuation of 
amphotericin B deoxycholate is considered during the 
period of neutropenia [2]. GM can be helpful to determine 
the discontinuation of antifungal therapy with no evidence 
of fungal infection in clinical or radiological examinations 
despite continuous neutropenia because its negative 
predictive value is high. On the contrary, when the level 
is positive, additional examinations, such as CT, are 
necessary [209,210,213,215]. Moreover, if fever persists 
even after the recovery of neutropenia, active efforts, such 
as radiological examinations, biopsy, and cultures, are 
needed to determine the cause of the fever.
CLOSING REMARKS
These guidelines represent an approximately 6-month 
effort. There were more studies in Korea than expected, 
but most were retrospective surveys conducted at a single 
hospital. These guidelines suggest drugs actually used 
as of December 2009 and their evidence, and if related 
Korean literature exists, it is also described. Although 
most questionnaire surveys performed in hospitals 
in Korea focused on clinical experiences based on the 
standard of reimbursement benefits, these guidelines 
attempt to provide an academic background for antibiotic 
therapy for febrile neutropenic patients. Thus, the 
contents of these guidelines may differ from the current 
notification of the Ministry of Health and Welfare and the 
standards of review of HIRA. In particular, the use and 
doses of antibiotics and the use of empirical antifungal 
therapy differ. Regarding the assessment of this guideline 
by specialists, the manuscript was revised by accepting 
opinions after presentations at five academic conferences 
in early 2010 and after the questionnaire survey had 
been conducted with related physicians in Korea. Of 
40 recommendations, 36 indicated appropriateness 
and 11 indicated the need for adjustment in over 10% 
of the respondents. Among them, seven were related 
to antibiotic prophylaxis. With the exception of these, 
there were opinions that some oral antibiotics, the use of 
glycopeptides, catheter-related infections, and empirical 
antifungal therapy need to be modified. This is believed to 
be because therapeutic strategies, including experiences, 
prophylaxis, distribution of causative organisms, and 
the current situation of resistance, differ according to 
hospitals. In future, we hope that clinical experiences in 
Korea help patients and are consistent with international 
standards through much discussion.
 This committee has attempted to develop guidelines that 
are helpful for clinicians who examine and have concern 
for patients. However, the current guidelines do not 
mention tuberculosis or chronic hepatitis, the incidence 
rates of which are expected to be characteristically high in 
Korea. Moreover, various guidelines for the diagnosis and 
treatment of common diseases (e.g., invasive aspergillosis) 
in febrile neutropenic patients and prevention of infectious 
complications in specific groups (e.g., HSCT recipients) 
are considered necessary. We hope that many researchers 
obtain the necessary additional data through prospective 
studies and suggest future directions. Finally, we hope that 
these guidelines are widely used and periodically revised 
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every few years by related societies to provide the latest 
treatment information based on literature from Korea and 
other countries.
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